Article published on 2023-12-16

Exploring Novel Herbal Compounds and Formulations for Inflammatory Bowel Disease (IBD) Management

Roshan Kumar Dubey[1*], Satyam Shukla[2]

[1]Department of Pharmaceutics, Mahatma Gandhi Institute of Pharmacy, Lucknow, Uttar Pradesh, India
[2]Department of Pharmacology, Mahatma Gandhi Institute of Pharmacy, Lucknow, Uttar Pradesh, India

***Correspondence Author:**
Roshan Kumar Dubey
Assistant Professor in the Department of Pharmaceutics
Mahatma Gandhi Institute of Pharmacy,
Lucknow, Uttar Pradesh, India
Email ID – pharmaroshan95@gmail.com

Chinese Journal of Applied Physiology, 2023: e20230003

Abstract Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents a complex and challenging clinical scenario characterized by chronic inflammation of the gastrointestinal tract. Traditional herbal medicine has garnered increasing interest as a potential adjunctive or alternative therapy for IBD, owing to its perceived efficacy, safety profile, and holistic approach to health. This review provides a comprehensive overview of the current landscape of herbal interventions for IBD, addressing scientific, regulatory, clinical, and patient-related considerations. Scientifically, the exploration of herbal interventions faces challenges related to the complexity of herbal formulations, standardization, and quality control. Regulatory hurdles encompass stringent requirements for safety, efficacy, and quality standards, necessitating adherence to robust preclinical and clinical protocols. Clinically, the heterogeneity of the patient population, potential interactions with conventional therapies, and patient preferences pose challenges in the integration of herbal interventions into clinical practice.

Keywords Inflammatory Bowel Disease (IBD), herbal interventions, traditional medicine, challenges, opportunities, future directions

1. Introduction

Inflammatory Bowel Disease (IBD) represents a significant challenge in modern healthcare, affecting millions of individuals worldwide. It encompasses two primary forms: Crohn's disease (CD) and ulcerative colitis (UC), both characterized by chronic inflammation of the gastrointestinal tract [1]. While the precise etiology of IBD remains incompletely understood, it is widely acknowledged to arise from a complex interplay of genetic predisposition, environmental triggers, immune dysregulation, and alterations in the gut microbiome [2].

The clinical manifestations of IBD are diverse, ranging from mild to severe symptoms such as abdominal pain, diarrhea, rectal bleeding, weight

DOI: 10.62958/j.cjap.2023.003
www.cjap.ac.cn

Published by CJAP editorial office and Asian BioMed Innovation Press

loss, fatigue, and impaired quality of life [3]. The disease course is typically characterized by periods of remission interspersed with episodes of disease flare-ups, further complicating management and necessitating long-term therapeutic strategies [4].

Conventional treatments for IBD aim to achieve and sustain remission, alleviate symptoms, prevent complications, and improve patients' overall well-being. These treatments include aminosalicylates, corticosteroids, immunomodulators (such as azathioprine and methotrexate), and biologic agents targeting specific inflammatory cytokines (e.g., tumor necrosis factor-alpha inhibitors like infliximab and adalimumab) [5]. While these therapies have revolutionized the management of IBD and significantly improved patient outcomes, they are not without limitations.

One of the primary challenges in IBD management is the variable response to conventional therapies among patients. While some individuals achieve sustained remission with minimal side effects, others may experience treatment failure, adverse reactions, or loss of response over time. Additionally, the long-term use of immunosuppressive medications may be associated with increased risks of infection, malignancy, and other adverse events, further underscoring the need for alternative therapeutic options [6].

Given these limitations, there has been a growing interest in exploring complementary and alternative approaches to IBD management. Herbal medicine, which encompasses a vast array of plant-derived compounds and formulations, has been utilized for centuries in various traditional healing systems across cultures and continents [7]. Traditional Chinese Medicine (TCM), in particular, offers a rich repository of herbal remedies and therapeutic approaches for gastrointestinal disorders, including IBD.

Herbal remedies have several potential advantages in the management of IBD. Firstly, many herbal compounds possess multifaceted pharmacological properties, targeting multiple pathways implicated in the pathogenesis of IBD, including inflammation, oxidative stress, mucosal healing, and modulation of the gut microbiota. Secondly, herbal therapies may offer a favorable safety profile compared to conventional medications, with potentially fewer adverse effects and reduced risks of long-term complications [8]. Thirdly, herbal medicine often emphasizes a holistic approach to health and wellness, addressing not only the physical symptoms of IBD but also the psychosocial and emotional aspects of the disease.

This paper aims to provide a comprehensive exploration of recent advancements in the identification, characterization, and evaluation of novel herbal compounds and formulations for the management of IBD. Through a meticulous review and synthesis of preclinical and clinical studies, we will elucidate the underlying mechanisms of action, efficacy, safety profile, and challenges associated with these herbal interventions [9]. By critically appraising the existing evidence base, we seek to elucidate



Figure 1: Diagrammatically representation of Inflammatory Bowel Disease (IBD)

the potential role of herbal medicine as a valuable adjunct or alternative therapy in the comprehensive management of IBD, thereby improving patient outcomes and quality of life [10].

2. Mechanisms of Action of Herbal Compounds in IBD

Herbal compounds utilized in the management of Inflammatory Bowel Disease (IBD) exert their therapeutic effects through a variety of mechanisms, targeting key pathways implicated in the disease's pathogenesis. These mechanisms can be broadly categorized into anti-inflammatory properties, antioxidant effects, and modulation of the gut microbiota [11]. Firstly, herbal compounds exhibit potent anti-inflammatory properties by targeting various components of the inflammatory cascade. For instance, compounds such as curcumin, quercetin, and resveratrol have been shown to inhibit the production and activity of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1β, IL-6). By suppressing the activation of nuclear factor-kappa B (NF-κB) and other inflammatory signaling pathways, these compounds help mitigate inflammation and reduce tissue damage in the gastrointestinal tract [12].

Secondly, many herbal compounds possess antioxidant properties that play a crucial role in combating oxidative stress, a hallmark feature of IBD. By scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defenses, compounds like curcumin, green tea catechins, and flavonoids protect intestinal epithelial cells from oxidative damage and promote mucosal healing. This antioxidant activity contributes to the overall anti-inflammatory effects of herbal interventions in IBD [13]. Lastly, herbal compounds exert effects on the gut microbiota, which plays a significant role in IBD pathogenesis and disease progression. Some compounds exhibit prebiotic effects, promoting the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli while inhibiting the proliferation of pathogenic microorganisms [14]. By restoring microbial diversity and balance in the gut microbiome, herbal interventions help modulate immune responses, reduce mucosal inflammation, and maintain intestinal barrier function.

Inflammatory Bowel Disease (IBD) is characterized by dysregulated immune responses, chronic inflammation, and tissue damage within the gastrointestinal tract. Herbal compounds used in the management of IBD exert their therapeutic effects through a diverse array of mechanisms, targeting key pathways involved in the pathogenesis of the disease [15]. Understanding these mechanisms is crucial for elucidating the potential therapeutic benefits of herbal interventions in IBD. Below, we delve into the primary mechanisms of action of herbal compounds in IBD:

a. Anti-inflammatory Properties

The anti-inflammatory properties of herbal compounds are fundamental to their therapeutic efficacy in managing Inflammatory Bowel Disease (IBD). These compounds, including curcumin, quercetin, and resveratrol, exert their effects by modulating the production and activity of pro-inflammatory cytokines implicated in IBD pathogenesis, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-12 (IL-12). By inhibiting the synthesis or release of these cytokines from immune cells, herbal compounds help mitigate mucosal inflammation and reduce tissue damage within the gastrointestinal tract [16]. Additionally, herbal compounds target the NF-κB pathway, a central regulator of inflammatory gene expression. Aberrant activation of NF-κB contributes to sustained inflammation in IBD. Compounds like berberine, andrographolide, and curcumin inhibit NF-κB activation and nuclear translocation, thereby suppressing the expression of pro-inflammatory genes involved in the inflammatory cascade [17]. This mechanism helps alleviate inflammation and attenuate disease severity in IBD patients.

Furthermore, herbal compounds exhibit immunomodulatory effects, balancing immune responses in the gut microenvironment. Polysaccharides from medicinal mushrooms like Ganoderma lucidum and Astragalus membranaceus enhance the function of regulatory T cells (Tregs) while suppressing pro-inflammatory T helper 17 (Th17) cells. This shift towards a regulatory immune phenotype helps mitigate mucosal inflammation and promote intestinal healing in IBD [18]. Another aspect of the anti-inflammatory action of herbal compounds involves reducing leukocyte infiltration and adhesion within the intestinal mucosa. Flavonoids and polyphenols found in herbs like green tea and ginger inhibit the expression of adhesion molecules on endothelial cells and leukocytes, preventing their interaction and migration into inflamed tissues. This mechanism helps limit immune cell infiltration and subsequent tissue damage in IBD [19].

b. Antioxidant Effects

The antioxidant effects of herbal compounds represent a crucial mechanism through which these natural substances exert therapeutic benefits in Inflammatory Bowel Disease (IBD) management. These effects are pivotal for counteracting oxidative stress, a hallmark feature of IBD pathogenesis, and play a vital role in promoting mucosal healing and reducing tissue damage within the gastrointestinal tract. Herbal compounds such as curcumin, green tea catechins (e.g., epigallocatechin gallate, EGCG), and flavonoids (e.g., quercetin, rutin) possess potent antioxidant properties, acting as scavengers of reactive oxygen species (ROS) [20]. By neutralizing free radicals and reactive species, these compounds alleviate oxidative stress and protect against cellular damage in the inflamed gut mucosa.

Moreover, herbal compounds stimulate the expression and activity of endogenous antioxidant enzymes, enhancing cellular antioxidant defense mechanisms [21]. Enzymes like superoxide dismutase (SOD), catalase, glutathione peroxidase, and heme oxygenase-1 (HO-1) are upregulated by compounds such as curcumin, contributing to increased enzymatic antioxidant activity and improved redox balance in the intestinal mucosa. This augmentation of the antioxidant defense system helps mitigate oxidative stress-induced injury and maintain cellular homeostasis in the inflamed gut microenvironment [22].

Preservation of intestinal barrier integrity is another critical aspect of the antioxidant effects of herbal compounds in IBD. Oxidative stress can compromise the integrity of the intestinal barrier, leading to increased permeability and translocation of luminal antigens into the mucosa, exacerbating inflammation and tissue damage. Herbal compounds with antioxidant properties prevent oxidative damage to tight junction proteins and mucosal epithelial cells, thereby preserving barrier integrity and limiting immune activation in the gut mucosa [23].

Furthermore, antioxidant compounds aid in promoting mucosal healing by reducing oxidative stress and supporting cellular proliferation and migration. EGCG, a polyphenol in green tea, stimulates epithelial cell proliferation and migration, accelerating mucosal healing in experimental models of colitis. Similarly, curcumin enhances mucosal repair by modulating growth factors and cytokines involved in wound healing processes [24]. These mechanisms collectively underscore the importance of antioxidant effects in herbal compounds for mitigating oxidative stress, preserving barrier function, promoting mucosal healing, and ultimately reducing tissue damage in IBD. Herbal interventions targeting oxidative mechanisms hold promise as therapeutic approaches for improving outcomes in patients with IBD [25].

c. Gut Microbiota Modulation

Gut microbiota modulation is a pivotal mechanism through which herbal compounds exert their therapeutic effects in Inflammatory Bowel Disease (IBD). The gut microbiota plays a critical role in maintaining intestinal homeostasis and immune function, and dysbiosis is commonly observed in IBD, contributing to disease pathogenesis. Herbal compounds possess the ability to modulate the gut microbiota by promoting beneficial bacterial populations while inhibiting the growth of pathogenic microbes [26]. This modulation contributes to the anti-inflammatory, immunomodulatory, and mucosal healing effects observed with herbal interventions in IBD.

Herbal compounds such as berberine, licorice root extract, and garlic derivatives exhibit prebiotic effects, promoting the growth of beneficial gut bacteria such as Bifidobacteria and Lactobacilli. By serving as substrates for beneficial bacteria, these compounds enhance their proliferation and metabolic activity, restoring microbial diversity and balance in the gut microbiota disrupted in IBD [27]. This restoration of microbial equilibrium contributes to the attenuation of mucosal inflammation and the maintenance of intestinal homeostasis.

Additionally, herbal compounds possess antimicrobial properties that can suppress the growth and virulence of pathogenic microorganisms implicated in IBD, such as adherent-invasive Escherichia coli (AIEC) and Clostridium difficile. By targeting pathogenic microbes directly, herbal interventions mitigate mucosal inflammation, prevent microbial translocation, and maintain intestinal barrier integrity, thus improving gut health and alleviating IBD symptoms [28].

Moreover, herbal compounds can influence microbial metabolism within the gut, leading to the production of bioactive metabolites with beneficial effects on host physiology. Certain polyphenols found in herbs like green tea and berries are metabolized by gut bacteria into bioactive compounds with anti-inflammatory and antioxidant properties [29]. By modulating microbial metabolism, herbal interventions contribute to the production of metabolites that promote intestinal health and mitigate inflammation in IBD.



Figure 2: The role of dietary polyphenols in Inflammatory Bowel Disease

Furthermore, herbal interventions contribute to the restoration of mucosal immune tolerance by promoting the expansion of regulatory T cells (Tregs) and inhibiting the proliferation of pro-inflammatory T helper 17 (Th17) cells [30]. By modulating the gut microbiota composition towards a more beneficial profile, herbal compounds restore mucosal immune tolerance and dampen excessive inflammation in the gut mucosa, thereby improving clinical outcomes in patients with IBD. Overall, gut microbiota modulation represents a key mechanism through which herbal interventions exert their therapeutic effects in IBD, offering promise as an effective approach for managing this chronic inflammatory condition [31].

3. Identification of Novel Herbal Compounds

The comprehensive process of identifying novel herbal compounds for the management of Inflammatory Bowel Disease (IBD) involves a rigorous and multifaceted approach that integrates various scientific methodologies and techniques [32, 33]. Initially, researchers delve into extensive literature reviews and databases to identify candidate herbal extracts or compounds with reported pharmacological activities relevant to IBD. These activities may include anti-inflammatory, antioxidant, immunomodulatory, or antimicrobial properties. Once potential candidates are identified, researchers move on to experimental validation through in vitro assays [34].

In vitro assays serve as an initial screening tool to

assess the bioactivity of herbal compounds. These assays often involve using cell culture models of intestinal epithelial cells, immune cells, or co-culture systems that mimic the gut microenvironment [35]. Parameters such as cell viability, cytokine production, nuclear factor-kappa B (NF-κB) activation, and antioxidant capacity are measured to evaluate the effects of herbal compounds on inflammation, oxidative stress, and immune responses relevant to IBD. Simultaneously, researchers explore the chemical composition of herbal extracts and compounds through techniques like high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy [36]. This chemical characterization helps identify and quantify bioactive constituents present in the herbal material, providing insights into potential mechanisms of action.

Following promising results from in vitro studies, researchers progress to preclinical evaluation using animal models of IBD. Various animal models, including chemically-induced colitis models (e.g., dextran sulfate sodium, TNBS, and oxazolone models) and genetically modified mice, are employed to assess the therapeutic effects of herbal interventions in vivo. Parameters such as disease activity index [37], histological scores, cytokine profiles, gut microbiota composition, and mucosal barrier integrity are evaluated to elucidate the efficacy and underlying mechanisms of action of herbal compounds.

Moreover, researchers explore the potential interactions between herbal compounds and the gut microbiota, considering the intricate relationship between the host and its microbial inhabitants. Techniques such as 16S rRNA gene sequencing and metagenomic analysis are employed to characterize changes in gut microbial composition and function following herbal intervention [38]. Parallel to preclinical studies, researchers conduct pilot clinical trials to evaluate the safety, tolerability, and preliminary efficacy of herbal interventions in human subjects with IBD. These trials involve recruiting patients with active or quiescent disease and administering herbal compounds or formulations over a specified period [39]. Clinical outcomes such as disease activity scores, clinical remission rates, mucosal healing, quality of life measures, and adverse events are monitored to assess the therapeutic potential of herbal interventions.

Throughout this iterative process, researchers refine their selection criteria, optimize dosing regimens, and elucidate mechanisms of action to further enhance the therapeutic efficacy of herbal interventions for IBD [40]. This systematic and interdisciplinary approach towards identifying novel herbal compounds underscores their potential as promising adjunctive or alternative therapies for the management of IBD, addressing the unmet needs of patients with this chronic and debilitating condition [41].

4. Preclinical Evidence Supporting Efficacy

Preclinical evidence supporting the efficacy of herbal compounds in the management of Inflammatory Bowel Disease (IBD) is extensive and multifaceted, spanning both in vitro and in vivo studies. In cell culture studies, herbal compounds such as curcumin, quercetin, and berberine have demonstrated notable anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines like TNF-α and IL-6, as well as modulating NF-κB signaling pathways in relevant cell types. These compounds have also shown promise in enhancing barrier function and promoting mucosal healing, providing valuable insights into their potential mechanisms of action [42].

Moreover, animal models of colitis have been instrumental in elucidating the therapeutic benefits of herbal interventions in vivo. Studies utilizing chemically-induced models or genetically modified mice have consistently demonstrated that herbal compounds like curcumin, resveratrol, and boswellia extract effectively ameliorate colitis severity, reduce inflammatory cytokine expression, and improve histological scores [43]. These compounds exert their effects through various mechanisms, including anti-inflammatory, antioxidant, and immunomodulatory actions, thus highlighting their potential as therapeutic agents for IBD.

Mechanistic studies conducted in preclinical settings have further deepened our understanding of how herbal compounds exert their beneficial effects in IBD. For instance, curcumin has been shown to inhibit NF-κB activation, suppress inflammatory cytokine production, enhance barrier function, and modulate gut microbiota composition in animal models of colitis. Similarly, quercetin exhibits antioxidant effects, inhibits pro-inflammatory signaling pathways, and promotes regulatory T cell function, underscoring the diverse mechanisms through which herbal compounds exert their therapeutic effects [44].

Furthermore, preclinical studies have contributed valuable insights into the pharmacokinetics and safety profiles of herbal compounds. Pharmacokinetic studies have revealed challenges such as poor oral

bioavailability and rapid metabolism for compounds like curcumin and berberine. Strategies to address these issues, such as nanoformulations or co-administration with absorption enhancers, are being explored to improve therapeutic efficacy [45]. Additionally, preclinical safety assessments help identify potential adverse effects associated with herbal interventions, guiding their further development and optimization for clinical use.

5. Clinical Trials Assessing Safety and Efficacy

Clinical trials evaluating the safety and efficacy of herbal interventions in Inflammatory Bowel Disease (IBD) undergo a rigorous process encompassing multiple phases and assessments to comprehensively evaluate their therapeutic potential. These trials typically adopt randomized controlled designs, which are considered the gold standard for assessing treatment efficacy. However, depending on the research objectives, observational studies and pilot trials may also be conducted. The recruitment process involves meticulous patient selection, considering factors such as disease subtype (Crohn's disease or ulcerative colitis), disease severity, duration, and previous treatment history. Patient demographics, baseline characteristics, and disease-related parameters are carefully documented to ensure homogeneity among study participants [46].

Herbal interventions are administered to the treatment arm, either as standalone therapies or in combination with conventional treatments, while control groups may receive placebo, standard-of-care treatments, or active comparators. The choice of comparator is guided by study objectives, ethical considerations, and existing evidence. Treatment regimens are meticulously designed, taking into account factors such as dosage, frequency, and duration of administration. Herbal formulations may vary in composition, bioavailability, and pharmacokinetic properties, necessitating careful consideration during trial design.

Clinical outcomes encompass a wide range of measures aimed at assessing treatment efficacy and safety comprehensively. Primary endpoints often include disease activity scores, clinical remission rates, mucosal healing, and quality of life measures. Secondary endpoints may involve inflammatory biomarkers (e.g., C-reactive protein, fecal calprotectin), endoscopic findings (e.g., mucosal inflammation, ulceration) [47], histological changes, and adverse events. Patient-reported outcomes, such as symptom severity, medication adherence, and treatment satisfaction, provide valuable insights into treatment tolerability and patient well-being.

Safety assessment is a paramount aspect of clinical trials evaluating herbal interventions. Adverse events, including gastrointestinal symptoms, allergic reactions, and changes in laboratory parameters, are closely monitored throughout the study period. Long-term safety data are collected to assess the risk of cumulative toxicity or adverse effects associated with prolonged use. Pharmacovigilance strategies, including regular monitoring and reporting of adverse events, are implemented to ensure patient safety and regulatory compliance [48].

Translational biomarkers serve as valuable tools for elucidating the mechanisms of action and pharmacodynamic effects of herbal interventions in IBD. Biomarkers such as inflammatory cytokines, gut microbiota composition, mucosal gene expression profiles, and serum metabolites are assessed to correlate treatment response with underlying biological changes [49]. These biomarkers provide mechanistic insights into the therapeutic effects of herbal interventions, facilitating the development of personalized treatment approaches and targeted therapies.

Subgroup analyses based on disease phenotype, treatment history, and genetic factors may be conducted to identify patient subpopulations that derive maximal benefit from herbal interventions. Exploratory endpoints, including dietary habits, psychosocial factors, and healthcare utilization, offer additional dimensions for evaluating treatment response and patient outcomes. Long-term follow-up assessments evaluate the durability of treatment effects and the risk of disease relapse or recurrence, providing insights into the maintenance of clinical remission and sustained improvements in disease outcomes [50].

6. Challenges and Considerations

The pursuit of herbal interventions for Inflammatory Bowel Disease (IBD) encounters an array of nuanced challenges and considerations, spanning scientific intricacies, regulatory complexities, clinical uncertainties, and patient-centric dynamics. Scientifically, the complexity of herbal formulations presents a labyrinth of challenges, as these remedies often consist of numerous bioactive compounds with intricate interactions. Deciphering the precise mechanisms of action and therapeutic efficacy amid

this complexity demands sophisticated analytical techniques and exhaustive experimentation [51, 52]. Standardization and quality control emerge as formidable tasks, imperative for ensuring uniformity and consistency across different batches of herbal products. Achieving this necessitates the development of robust methodologies and stringent regulatory standards to validate the composition, potency, and purity of herbal interventions [53].

Regulatory scrutiny looms large over the landscape of herbal medicine, with stringent requirements imposed by regulatory bodies to safeguard public health and ensure product efficacy [54]. Navigating the intricate web of regulatory frameworks demands meticulous adherence to preclinical and clinical protocols, accompanied by exhaustive documentation and rigorous compliance measures [55]. The journey from laboratory bench to clinical bedside is fraught with regulatory hurdles, with approval processes often protracted and arduous. Accurate labeling of herbal products emerges as a critical imperative, with regulatory guidelines dictating stringent requirements for ingredient disclosure, dosage instructions, and potential adverse effects. The onus lies on manufacturers and distributors to ensure adherence to these regulations, thereby fostering transparency and accountability in the herbal supplement industry [56, 57].

Clinically, the diverse and heterogeneous nature of the patient population poses significant challenges in the application of herbal interventions for IBD. Patient variability in disease phenotype, severity, treatment response, and comorbidities necessitates a personalized approach to treatment, tailored to individual patient profiles and disease characteristics [58]. The potential for interactions between herbal remedies and conventional therapies further complicates clinical decision-making, warranting vigilant monitoring and proactive management strategies [59, 60]. The integration of herbal interventions into the existing treatment paradigm requires careful consideration of efficacy, safety, and patient preferences, with healthcare providers assuming the pivotal role of guiding patients through informed decision-making processes [61].

Patient-related considerations cast a spotlight on the intricate interplay between cultural beliefs, personal preferences, and treatment adherence in the realm of herbal medicine. Patient attitudes towards herbal interventions are shaped by a myriad of factors, including cultural heritage, socioeconomic status, and prior experiences with conventional medicine [62]. Addressing patient concerns and misconceptions surrounding herbal therapies necessitates open communication, patient education, and shared decision-making approaches. Safety monitoring emerges as a paramount concern, with patients and healthcare providers alike tasked with vigilantly monitoring for adverse effects, allergic reactions, and potential drug interactions [63].

In the realm of research and education, the pursuit of herbal interventions for IBD unfolds against a backdrop of knowledge gaps, methodological challenges, and regulatory ambiguities. High-quality evidence from well-designed clinical trials remains sparse, underscoring the need for further research to establish the safety and efficacy of herbal interventions definitively [64]. Provider education emerges as a cornerstone of successful integration, with healthcare professionals requiring comprehensive training and continuing education to navigate the complexities of herbal medicine effectively [65]. Collaborative efforts between researchers, clinicians, regulatory agencies, and patients are essential to drive progress in the field, fostering an environment conducive to evidence-based practice, patient-centered care, and regulatory compliance.

In essence, while herbal interventions hold promise as complementary or alternative therapies for IBD, their integration into clinical practice necessitates a multifaceted approach, addressing scientific, regulatory, clinical, and patient-related challenges with nuance and diligence. By surmounting these challenges through collaborative efforts and evidence-based strategies, herbal interventions have the potential to enrich the therapeutic armamentarium for IBD, offering patients a holistic and personalized approach to care [66].

7. Future Directions and Integration into Clinical Practice

The future directions for herbal interventions in the management of Inflammatory Bowel Disease (IBD) are poised to evolve along several interconnected pathways, encompassing scientific innovation, regulatory advancements, clinical integration, and patient-centered care [67]. As research continues to unravel the intricate mechanisms underlying the therapeutic effects of herbal compounds, future investigations are likely to focus on elucidating the specific bioactive constituents, molecular targets, and pathways involved [68]. This deeper understanding of herbal pharmacology will pave the way for the development of targeted therapies, precision medicine

approaches, and novel drug formulations tailored to individual patient profiles and disease characteristics. Advancements in technology, including high-throughput screening, computational modeling, and omics technologies, hold promise for accelerating the discovery and optimization of herbal interventions [69]. Integrating these cutting-edge methodologies into preclinical research efforts will enable researchers to identify novel bioactive compounds, predict their pharmacokinetic properties, and optimize their therapeutic efficacy. Moreover, the advent of personalized medicine approaches, leveraging genetic, epigenetic, and microbiome data, will facilitate the stratification of patients based on their unique biological signatures, thereby enabling tailored treatment regimens and optimizing therapeutic outcomes.

On the regulatory front, efforts to standardize and harmonize regulatory frameworks for herbal interventions are poised to streamline the approval process and enhance market access. Collaborative initiatives between regulatory agencies, industry stakeholders, and academic institutions will foster the development of evidence-based guidelines, quality standards, and safety protocols for herbal products [70]. Robust post-market surveillance systems and pharmacovigilance mechanisms will play a crucial role in monitoring the safety and efficacy of herbal interventions in real-world settings, thereby ensuring continued patient safety and regulatory compliance. Clinically, the integration of herbal interventions into the existing treatment paradigm for IBD will require a multidisciplinary approach, involving collaboration between healthcare providers, researchers,

Table 1: Herbal Plant used in the treatment of Inflammatory Bowel Disease (IBD)

Plant	Scientific Name	Properties/Components	Potential Benefits for IBD
Aloe Vera	*Aloe barbadensis miller*	Anti-inflammatory	May help reduce inflammation in the intestines and promote healing of the intestinal lining.
Turmeric	*Curcuma longa*	Curcumin	Contains potent anti-inflammatory and antioxidant properties; may help reduce inflammation and alleviate symptoms such as abdominal pain and diarrhea.
Boswellia	*Boswellia serrata*	Boswellic acids	Studies suggest potential benefits in reducing inflammation and improving symptoms of IBD by inhibiting pro-inflammatory enzymes.
Slippery Elm	*Ulmus rubra*	Mucilage	The mucilage in slippery elm bark can coat and soothe the lining of the intestines, potentially reducing inflammation and easing symptoms such as diarrhea and abdominal discomfort.
Marshmallow Root	*Althaea officinalis*	Mucilage	Contains mucilage, which can soothe and protect the mucous membranes of the digestive tract, potentially alleviating inflammation and irritation associated with IBD.
Chamomile	*Matricaria chamomilla*	Anti-inflammatory	Known for its anti-inflammatory and calming properties; may help reduce inflammation in the intestines and alleviate symptoms such as abdominal pain and cramping.
Peppermint	*Mentha x piperita*	Peppermint oil	May help relax intestinal muscles, reduce abdominal pain and discomfort, and alleviate symptoms such as bloating and gas. However, caution is advised for individuals sensitive to peppermint.
Ginger	*Zingiber officinale*	Gingerol	Contains anti-inflammatory and antioxidant properties; may help reduce inflammation in the gut and alleviate symptoms of IBD such as nausea, vomiting, and abdominal pain.

pharmacists, and patients. Incorporating herbal medicine into clinical practice guidelines, treatment algorithms, and decision-support tools will empower healthcare professionals to make informed decisions about the use of herbal interventions in conjunction with conventional therapies. Provider education and training programs will play a pivotal role in enhancing healthcare professionals' knowledge, competence, and confidence in prescribing herbal interventions, thereby facilitating their seamless integration into clinical practice [71].

Patient-centered care emerges as a central tenet in the integration of herbal interventions into clinical practice, with an emphasis on shared decision-making, informed consent, and holistic patient support. Empowering patients with accurate information, education, and resources will enable them to make informed choices about their treatment options,

Table 2: List of Medicine available in the market for the treatment of Inflammatory Bowel Disease (IBD)

Medication Category	Examples	Mechanism of Action	Indications	Administration	Side Effects
Aminosalicylates (5-ASAs)	Mesalamine, sulfasalazine, balsalazide, olsalazine	Inhibition of inflammatory mediators in intestinal lining	Mild to moderate ulcerative colitis; maintenance of remission	Oral, rectal suppositories, enemas	Nausea, abdominal pain, diarrhea, headache, rare cases of kidney or liver problems
Corticosteroids	Prednisone, prednisolone, budesonide		Acute flares or severe symptoms of IBD	Oral, rectal (suppositories, enemas), IV	Weight gain, increased blood sugar levels, osteoporosis, hypertension, mood changes, increased susceptibility to infections
Immunomodulators	Azathioprine,	Suppression of immune system activity	Maintenance of remission in moderate to severe IBD; steroid-sparing agent	Oral, subcutaneous injection	Nausea, vomiting, liver toxicity, pancreatitis, bone marrow suppression, increased risk of infections
Biologic Therapies	Infliximab, adalimumab, vedolizumab, ustekinumab	Target specific molecules in the inflammatory response	Moderate to severe IBD not responsive to other treatments; or intolerance	Intravenous infusion, subcutaneous injection	Increased risk of infections, infusion/ injection site reactions, serious adverse events such as reactivation of latent infections, or autoimmune disorders
Antibiotics	Metronidazole, ciprofloxacin, rifaximin	Reduce inflammation; treat bacterial overgrowth	Complicated Crohn's disease; bacterial overgrowth	Oral, intravenous	Nausea, diarrhea, abdominal pain, antibiotic resistance, disruption of gut microbiota
Symptom-Based Medications	Loperamide, acetaminophen, dicyclomine	Alleviate specific symptoms associated with IBD	Diarrhea, abdominal pain, cramping	Oral	Constipation, dizziness, drowsiness, dry mouth

preferences, and goals of care. Culturally sensitive approaches that respect patients' beliefs, values, and cultural backgrounds will foster trust, engagement, and adherence to treatment regimens, thereby enhancing treatment outcomes and quality of life, table shows the list of : Herbal Plant used in the treatment of Inflammatory Bowel Disease (IBD) and table 2 shows the List of Medicine available in the market for the treatment of Inflammatory Bowel Disease (IBD).

8. Conclusion

In conclusion, the exploration of herbal interventions for Inflammatory Bowel Disease (IBD) represents a dynamic and evolving field at the intersection of traditional medicine, scientific inquiry, and clinical practice. Throughout this journey, researchers, clinicians, regulatory agencies, and patients have encountered a myriad of challenges and considerations, spanning scientific complexities, regulatory hurdles, clinical uncertainties, and patient-centric dynamics. Despite these challenges, the landscape of herbal medicine holds immense promise, with opportunities for scientific innovation, regulatory advancement, clinical integration, and patient-centered care. As research continues to unravel the intricate mechanisms underlying the therapeutic effects of herbal compounds, future investigations are poised to focus on precision medicine approaches, personalized treatment regimens, and novel drug formulations tailored to individual patient profiles and disease characteristics. Advances in technology, including high-throughput screening and omics technologies, will accelerate the discovery and optimization of herbal interventions, paving the way for targeted therapies and tailored treatment strategies.

On the regulatory front, efforts to standardize and harmonize regulatory frameworks for herbal interventions will enhance market access and ensure continued patient safety. Robust post-market surveillance systems and pharmacovigilance mechanisms will monitor the safety and efficacy of herbal interventions in real-world settings, fostering regulatory compliance and public trust.

Clinically, the integration of herbal interventions into the existing treatment paradigm for IBD requires a multidisciplinary approach, involving collaboration between healthcare providers, researchers, pharmacists, and patients. Provider education and training programs will enhance healthcare professionals' knowledge and competence in prescribing herbal interventions, while patient-centered approaches will empower patients to make informed choices about their treatment options and preferences.

In summary, the future of herbal interventions in IBD holds great promise, with opportunities to revolutionize the landscape of care and improve outcomes for patients worldwide. By embracing a holistic, evidence-based approach and fostering collaboration across stakeholders, we can unlock the full potential of herbal medicine, offering patients a personalized, effective, and sustainable approach to managing their disease. Through concerted efforts and strategic investments, herbal interventions have the potential to transform the way we understand, treat, and ultimately, overcome the challenges of IBD.

Acknowledgement

The authors acknowledge to Mahatma Gandhi Institute of Pharmacy, Lucknow, U. P. India, for provided necessary facility.

Author contribution

All authors contributed to the idea and design of the review, with drafting of the article, and revision of the article.

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. W. Feng, L. Zhu, H. Shen, Traditional Chinese medicine alleviates ulcerative colitis via modulating gut microbiota, Evid. Based Complement. Alternat. Med. (2022) 8075344.
2. J. Zou, Y. Shen, M. Chen, Lizhong decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and its metabolites, Appl. Microbiol. Biotechnol. 104 (2020) 5999–6012.
3. H. Zeng, S. Umar, B. Rust, D. Lazarova, M. Bordonaro, Secondary bile acids and short chain fatty acids in the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer, Int. J. Mol. Sci. 20 (2019) 1214.
4. A. Visekruna, M. Luu, The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis, Front. Cell Dev. Biol. 9 (2021) 703218.
5. A. Lavelle, H. Sokol, Gut microbiota-derived metabolites as key actors in inflammatory bowel disease, Nat. Rev. Gastroenterol. Hepatol. 17 (2020) 223–237.
6. M. Sun, W. Wu, Z. Liu, Y. Cong, Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases, J. Gastroenterol. 52 (2017) 1–8.

7. P.M. Smith, M.R. Howitt, N. Panikov, The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis, Science 341 (2013) 569–573.
8. M. Lyu, Y.F. Wang, G.W. Fan, X.Y. Wang, S.Y. Xu, Y. Zhu, Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota, Front. Microbiol. 8 (2017) 2146.
9. Z. Sun, J. Li, Y. Dai, Indigo naturalis alleviates dextran sulfate sodium-induced colitis in rats via altering gut microbiota, Front. Microbiol. 11 (2020) 731.
10. W.J. Lv, C. Liu, Y.F. Li, Systems pharmacology and microbiome dissection of shen ling bai zhu san reveal multiscale treatment strategy for IBD, Oxid. Med. Cell Longev (2019) 8194804.
11. D. Gu, S. Zhou, L. Yao, Effects of ShenLing BaiZhu san supplementation on gut microbiota and oxidative stress in rats with ulcerative colitis, Evid. Based Complement. Alternat. Med. (2021) 3960989.
12. X. Huang, Z. Chen, M. Li, Herbal pair Huangqin-Baishao: mechanisms underlying inflammatory bowel disease by combined system pharmacology and cell experiment approach, BMC Complement. Med. Ther. 20 (2020) 292.
13. L. Zhu, L.Z. Xu, S. Zhao, Z.F. Shen, H. Shen, L.B. Zhan, Protective effect of baicalin on the regulation of Treg/Th17 balance, gut microbiota and short-chain fatty acids in rats with ulcerative colitis, Appl. Microbiol. Biotechnol. 104 (2020) 5449–5460.
14. N. Molinero, L. Ruiz, B. S´anchez, A. Margolles, S. Delgado, Intestinal bacteria interplay with bile and cholesterol metabolism: implications on host physiology, Front. Physiol. 10 (2019) 185.
15. B. Stanimirov, K. Stankov, M. Mikov, Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases, Hepatobiliary Pancreat. Dis. Int. 14 (2015) 18–33.
16. J. Torres, C. Palmela, H. Brito, The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease, United, Eur. Gastroenterol. J. 6 (2018) 112–122.
17. J. Hu, H. Huang, Y. Che, Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function, J. Ethnopharmacol. 266 (2021) 113394.
18. Y.L. Hua, Y.Q. Jia, X.S. Zhang, Baitouweng Tang ameliorates DSS-induced ulcerative colitis through the regulation of the gut microbiota and bile acids via pathways involving FXR and TGR5, Biomed. Pharmacother. 137 (2021) 111320.
19. H. Cheng, X. Guan, D. Chen, W. Ma, The Th17/Treg cell balance: a gut microbiotamodulated story, Microorganisms 7 (2019) 583.
20. D.A. Hill, D. Artis, Intestinal bacteria and the regulation of immune cell homeostasis, Annu. Rev. Immunol. 28 (2010) 623–667.
21. H. Cheng, J. Liu, Y. Tan, W. Feng, C. Peng, Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine, J. Pharm. Anal. 12 (2022) 541–555.
22. H. Cui, Y. Cai, L. Wang, Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon, Front. Pharmacol. 9 (2018) 571.
23. W. Zhang, C. Cheng, Q. Han, Flos abelmoschus manihot extract attenuates DSSinduced colitis by regulating gut microbiota and Th17/Treg balance, Biomed. Pharmacother. 117 (2019) 109162.
24. S. Luo, R. Wen, Q. Wang, Rhubarb peony decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance, J. Ethnopharmacol. 231 (2019) 39–49.
25. K. Hiippala, H. Jouhten, A. Ronkainen, The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation, Nutrients 10 (2018) 988.
26. B. Yue, Z.L. Yu, C. Lv, X.L. Geng, Z.T. Wang, W. Dou, Regulation of the intestinal microbiota: an emerging therapeutic strategy for inflammatory bowel disease, World J. Gastroenterol. 26 (2020) 4378–4393.
27. Z. Sun, J. Li, W. Wang, Qingchang wenzhong decoction accelerates intestinal mucosal healing through modulation of dysregulated gut microbiome, intestinal barrier and immune responses in mice, Front. Pharmacol. 12 (2021) 738152.
28. R. Wang, T. Chen, Q. Wang, Total flavone of abelmoschus manihot ameliorates stress-induced microbial alterations drive intestinal barrier injury in DSS colitis, Drug Des. Devel. Ther. 15 (2021) 2999–3016.
29. N. Hasan, H. Yang, Factors affecting the composition of the gut microbiota, and its modulation, PeerJ (2019) 7502.
30. A.P. Kaur, S. Bhardwaj, D.S. Dhanjal, E. Nepovimova, et al., Plant prebiotics and their role in the amelioration of diseases, Biomolecules 3 (2021) 440.
31. J. Li, D. Li, Y. Chen, W. Chen, et al., Gut microbiota and aging: traditional Chinese medicine and modern medicine, Clin. Interv. Aging. 18 (2023) 963–986.
32. T.L. Lin, C.C. Lu, W.F. Lai, et al., Role of gut microbiota in identification of novel TCM-derived active metabolites, Protein Cell 5 (2021) 394–410.
33. H.Y. Zhang, J.X. Tian, F.M. Lian, Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota, Biomed. Pharmacother. 133 (2021) 110857.
34. A. Nishida, R. Inoue, O. Inatomi, S. Bamba, Y. Naito, A. Andoh, Gut microbiota in the pathogenesis of inflammatory bowel disease, Clin. J. Gastroenterol. 11 (2018) 1–10.
35. X.Y. Guo, X.J. Liu, J.Y. Hao, Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment, J. Dig. Dis. 21 (2020) 147–159.
36. M.C. Mentella, F. Scaldaferri, M. Pizzoferrato, A. Gasbarrini, Nutrition, IBD and gut microbiota: a review, Nutrients 12 (2020) 944.
37. J. Miyoshi, E.B. Chang, The gut microbiota and inflammatory bowel diseases, Transl. Res. 179 (2017) 38–48.
38. R. Pittayanon, J.T. Lau, G.I. Leontiadis, Differences in gut

microbiota in patients with vs without inflammatory bowel diseases: a systematic review, Gastroenterology 158 (2020) 930–946.
39. A. Elangovan, J.R. Allegretti, M. Fischer, Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation, Expert Opin. Biol. Ther. 19 (2019) 1343–1355.
40. S. Tkach, A. Dorofeyev, I. Kuzenko, Current status and future therapeutic options for fecal microbiota transplantation, Medicina (Kaunas). 58 (2022) 84.
41. M. Schultz, Clinical use of E. coli Nissle 1917 in inflammatory bowel disease, Inflamm. Bowel Dis. 14 (2008) 1012–1018.
42. S. Paramsothy, R. Paramsothy, D.T. Rubin, Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis, J. Crohns. Colitis 11 (2017) 1180–1199.
43. S.P. Costello, W. Soo, R.V. Bryant, V. Jairath, A.L. Hart, J.M. Andrews, Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis, Aliment. Pharmacol. Ther. 46 (2017) 213–224.
44. J.F. Stevens, C.S. Maier, The chemistry of gut microbial metabolism of polyphenols, Phytochem. Rev. 15 (2016) 425–444.
45. Y. Zheng, X. Gou, L. Zhang, Interactions between gut microbiota, host, and herbal medicines: a review of new insights into the pathogenesis and treatment of type 2 diabetes, Front. Cell. Infect. Microbiol. 10 (2020) 360.
46. A. Kaoutari, F. Armougom, J.I. Gordon, D. Raoult, B. Henrissat, The abundance and variety of carbohydrate-active enzymes in the human gut microbiota, Nat. Rev. Microbiol. 11 (2013) 497–504.
47. S.A. Zahran, M. Ali-Tammam, A.M. Hashem, R.K. Aziz, A.E. Ali, Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota, Sci. Rep. 9 (2019) 5508.
48. R. Feng, J.W. Shou, Z.X. Zhao, Transforming berberine into its intestine-absorbable form by the gut microbiota, Sci. Rep. 5 (2015) 12155.
49. X. Wu, S. Wang, J. Lu, Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives, Chin. Med. 13 (2018) 4.
50. J. Xu, H.B. Chen, S.L. Li, Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota, Med. Res. Rev. 37 (2017) 1140–1185.
51. X. Wang, L. Xie, J. Long, Therapeutic effect of Baicalin on inflammatory bowel disease: a review, J. Ethnopharmacol. 283 (2022) 114749.
52. T. Akao, K. Kawabata, E. Yanagisawa, Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form, J. Pharm. Pharmacol. 52 (2000) 1563–1568.
53. S.J. Yue, W.X. Wang, J.G. Yu, Gut microbiota modulation with traditional Chinese medicine: a system biology-driven approach, Pharmacol. Res. 148 (2019) 104453.
54. T.L. Lin, C.C. Lu, W.F. Lai, Role of gut microbiota in identification of novel TCMderived active metabolites, Protein Cell 12 (2021) 394–410.
55. W. Feng, J. Liu, L. Huang, Y. Tan, C. Peng, Gut microbiota as a target to limit toxic effects of traditional Chinese medicine: implications for therapy, Biomed. Pharmacotherap. 133 (2021) 111047.
56. G. Pan, B. Liu, S. Li, Kuijieling, a Chinese medicine alleviates DSS-induced colitis in C57BL/6Jmouse by improving the diversity and function of gut microbiota, FEMS Microbiol. Lett. 367 (2020).
57. H. Wu, Q. Rao, G.C. Ma, X.H. Yu, C.E. Zhang, Z.J. Ma, Effect of triptolide on dextran sodium sulfate-induced ulcerative colitis and gut microbiota in mice, Front. Pharmacol. 10 (2020) 1652.
58. M. Guo, S. Ding, C. Zhao, Red Ginseng and Semen Coicis can improve the structure of gut microbiota and relieve the symptoms of ulcerative colitis, J. Ethnopharmacol. 162 (2015) 7–13.
59. X. An, Q. Bao, S. Di, The interaction between the gut Microbiota and herbal medicine, Biomed. Pharmacother. 118 (2019) 109252.
60. P. Liu, Y. Bian, T. Liu, Huai hua san alleviates dextran sulphate sodium-induced colitis and modulates colonic microbiota, J. Ethnopharmacol. 259 (2020) 112944.
61. X. Hu, W. Liu, M. He, Comparison of the molecular mechanisms of Fuzi Lizhong Pill and Huangqin decoction in the treatment of the cold and heat syndromes of ulcerative colitis based on network pharmacology, Comput. Biol. Med. 159 (2023) 106870.
62. P. Wei, Q. He, T. Liu, Baitouweng decoction alleviates dextran sulfate sodiuminduced ulcerative colitis by suppressing leucine-related mTORC1 signaling and reducing oxidative stress, J. Ethnopharmacol. 304 (2023) 116095.
63. S.M. Pan, C.L. Wang, Z.F. Hu, Baitouweng decoction repairs the intestinal barrier in DSS-induced colitis mice via regulation of AMPK/mTOR-mediated autophagy, J. Ethnopharmacol. 318 (2024) 116888.
64. Y. Yang, Y. Wang, L. Zhao, Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis, Chin. Herb Med. 1 (2023) 181–200.
65. Q. Zhao, X.Y. Chen, C. Martin, Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants, Sci. Bull. 61 (2016) 1391–1398.
66. Y.Z. Lan, Y.L. Bai, X.D. Zhu, Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes: a protocol for systematic review and metaanalysis, Medicine 100 (2021).
67. W.W. Tao, H. Jiang, X.M. Tao, P. Jiang, L.Y. Sha, X.C. Sun, Effects of Acupuncture, Tai Chi Tuina, Qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: a metaanalysis, J. Pain Symptom Manage. 51 (2016) 728–747.
68. X.X. Sang, Z.X. Wang, S.Y. Liu, R.L. Wang, Relationship between Traditional Chinese Medicine(TCM)constitut ion and TCM syndrome in the diagnosis and treatment of chronic diseases, Chin. Med. Sci. J. 33 (2018) 114–

119.
69. J. Pun, W. Chor, Use of questioning between traditional Chinese medicine practitioners and patients to realize TCM philosophy: holism, five elements and yin-yang in the context of doctor-patient communication, Health Commun. 37 (2022) 163–176.
70. Z.X. Yan, Y.M. Liu, T. Ma, et al., Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: a meta-analysis of randomized controlled trials, Complement. Ther. Clin. Pract. 42 (2021) 101278.
71. Y. Wang, X. Gao, X. Zhang, Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease, Gut Microbes 13 (2021) 1–18.